171564-48-0Relevant articles and documents
CYCLIC PEPTIDE ANTIBIOTICS
-
Paragraph 00333, (2020/09/27)
Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.
MACROCYCLIC LRRK2 KINASE INHIBITORS
-
Page/Page column 177; 178, (2016/04/09)
The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
Total synthesis of (-)-aplaminal
Smith III, Amos B.,Liu, Zhuqing
supporting information; experimental part, p. 4363 - 4365 (2009/06/06)
(Chemical Equation Presented) The total synthesis and assignment of absolute configuration of (-)-aplaminal (1), a cytotoxic metabolite from a sea hare possessing a triazobicyclo[3.2.1]octane skeleton, has been achieved. The synthesis entailed condensatio
